The iShares Biotechnology ETF is a passively managed, market-capitalization-weighted fund that seeks to track the Nasdaq Biotechnology Index before fees and expenses. Sponsored by BlackRock, the fund carries an expense ratio of 0.44% and holds roughly 250 positions, with essentially all portfolio exposure concentrated in the healthcare sector.
Because the ETF is market-cap weighted, its trajectory is driven disproportionately by its largest constituents. Top holdings include GILD (Gilead Sciences), VRTX (Vertex Pharmaceuticals), AMGN (Amgen), REGN (Regeneron Pharmaceuticals), and MRNA (Moderna), alongside Natera, argenx, Illumina, and Revolution Medicines. The top 10 names account for roughly 49% of assets, giving the fund a tilt toward larger, more established biopharma companies rather than small-cap, clinical-stage firms.
Structurally, this positioning means the ETF is less exposed to the extreme binary outcomes of early-stage drug developers and more sensitive to commercial execution, pipeline readouts, and M&A activity among mid- and large-cap players. For investors, that translates into a future outlook shaped by the sector's established leaders rather than speculative names.
The macro backdrop for biotechnology is defined by the intersection of interest rates, inflation, and risk appetite. Even after a strong run, biotech valuations have traded at a discount to the broader market on a forward price-to-earnings basis, with projected earnings growth in the sector historically outpacing the S&P 500. That relative value underpins the constructive long-term case but does not insulate the group from rate-driven drawdowns.
On the index level, the Nasdaq Biotechnology Index's market-cap-weighted structure means the largest, often profitable biopharma companies anchor performance, providing a degree of defensive ballast compared with equal-weighted biotech strategies. However, the fund remains high-volatility by broad-market standards, reflecting the sector's reliance on clinical, regulatory, and financing outcomes. Macro trends such as easing policy, resilient economic growth, and a rotation away from heavily concentrated technology leadership could all support renewed inflows into the asset class.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It aims to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking the biotechnology space, tools like this can complement fundamental analysis by adding a data-driven view of short- to medium-term trend direction. Explore the Trend Prediction Engine to see how it may fit into your research process.
Several durable forces could support biotechnology over the long run. An aging global population is expanding demand for chronic and age-related disease treatments, while advances in gene editing, cell therapy, and precision medicine are broadening the addressable pipeline. The GLP-1 class has opened a large and fast-growing metabolic and obesity market, and the application of AI to drug discovery could structurally improve R&D productivity and returns across the industry.
At the same time, market structure is shifting. Patent expirations are pushing large pharma toward acquisitions, potentially providing a persistent valuation floor for innovative smaller and mid-cap developers. Interest-rate cycles will continue to influence financing conditions, but a more accommodative regulatory environment for deal-making and a gradual normalization of rates could reinforce the sector's structural appeal. These long-term drivers form the foundation of the ETF's future outlook, even as near-term volatility remains a core characteristic of the asset class.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PFIG | 23.35 | 0.09 | +0.39% |
| Invesco Fundamental Investment Grade Corporate Bond ETF (PFIG) | |||
| FLDB | 50.27 | -0.04 | -0.09% |
| Fidelity Low Duration Bond ETF (FLDB) | |||
| BSJY | 23.55 | -0.11 | -0.47% |
| Invesco BulletShares 2034 High Yield Corporate Bond ETF (BSJY) | |||
| GDV | 26.83 | -0.93 | -3.35% |
| Gabelli Dividend & Income Trust (The) | |||
| YBIT | 14.21 | -0.84 | -5.58% |
| Yieldmax Bitcoin Option Income Strategy ETF | |||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| YBIT | 14.21 | -0.84 | -5.58% |
| Yieldmax Bitcoin Option Income Strategy ETF | |||
| GDV | 26.83 | -0.93 | -3.35% |
| Gabelli Dividend & Income Trust (The) | |||
| BSJY | 23.55 | -0.11 | -0.47% |
| Invesco BulletShares 2034 High Yield Corporate Bond ETF (BSJY) | |||
| FLDB | 50.27 | -0.04 | -0.09% |
| Fidelity Low Duration Bond ETF (FLDB) | |||
| PFIG | 23.35 | 0.09 | +0.39% |
| Invesco Fundamental Investment Grade Corporate Bond ETF (PFIG) | |||
A.I.dvisor indicates that over the last year, IBB has been closely correlated with IBBQ. These tickers have moved in lockstep 99% of the time. This A.I.-generated data suggests there is a high statistical probability that if IBB jumps, then IBBQ could also see price increases.
| Ticker / NAME | Correlation To IBB | 1D Price Change % | ||
|---|---|---|---|---|
| IBB | 100% | -2.05% | ||
| IBBQ - IBB | 99% Closely correlated | -1.70% | ||
| BBH - IBB | 94% Closely correlated | -1.31% | ||
| PBE - IBB | 91% Closely correlated | -1.67% | ||
| CANC - IBB | 90% Closely correlated | -2.06% | ||
| GNOM - IBB | 87% Closely correlated | -2.57% | ||
More | ||||
IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 42 cases where IBB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 276 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 220 of 244 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
IBB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.